PTCT:NASDAQ
PTC Therapeutics, Inc.
$63.49
arrow_upward
+0.21%(+0.13) 1D
Nov 13, 4:00:00 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for PTCT...
Open
$63.12
High
$63.74
Low
$62.51
Mkt. cap
5.30B
Avg. vol.
1.09M
Volume
30.00
52-wk high
$90.87
52-wk low
$58.80
EPS
-$1.38
Beta
0.52
Shares outstanding
83.54M
No. of employees
991
Open
$63.12
High
$63.74
Low
$62.51
Mkt. cap
5.30B
Avg. vol.
1.09M
Volume
30.00
52-wk high
$90.87
52-wk low
$58.80
EPS
-$1.38
Beta
0.52
Shares outstanding
83.54M
No. of employees
991
News stories
From web sources and news partners
TradingView
·
37 minutes ago
PTCT: Sephience launch momentum supports a $2 billion-plus opportunity and 2027 growth plans
Investing.com
·
49 minutes ago
PTC Therapeutics at Jefferies Global Healthcare Conference: growth broadens
Profile
PTC Therapeutics, Inc. is an U.S.-based pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapies that alter gene expression via post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
FoundedJan 1, 1998
HeadquartersWarren, New Jersey, United States
SectorHealth Care
IndustryBiotechnology
Websiteptcbio.com